Tau protein hyperphosphorylation and aggregation in alzheimer’s disease and other tauopathies, and possible neuroprotective strategies

Biomolecules

Volumn 6, Issue 1, 2016, Pages 2-28

  Šimić, Goran ^a   Babić Leko, Mirjana ^a   Wray, Selina ^b   Harrington, Charles ^c   Delalle, Ivana ^d   Jovanov Milošević, Nataša ^a   Bažadona, Danira ^e   Buée, Luc ^f   de Silva, Rohan ^b   Giovanni, Giuseppe Di ^g,h   Wischik, Claude ^c   Hof, Patrick R ⁱ  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KBC Zagreb   (Croatia)

^f JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^g UNIVERSITY OF MALTA   (Malta)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer s disease; Amyloid ; Microtubules; Neurofibrillary degeneration; Neuropathology; Phosphorylation; Protein aggregation; Protein oligomerization; Tau protein; Tauopathies

Indexed keywords

ACTIN; APOLIPOPROTEIN E; CASPASE 3; DODECYL SULFATE SODIUM; HISTONE DEACETYLASE 6; INTERLEUKIN 1BETA CONVERTING ENZYME; MERCAPTOETHANOL; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2; N ACETYLGLUCOSAMINE; PHOSPHOLIPASE C GAMMA; POSTSYNAPTIC DENSITY PROTEIN 95; PRESENILIN 2; SYNAPTOPHYSIN; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; VIMENTIN; AMYLOID BETA PROTEIN; MAPT PROTEIN, HUMAN; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANTIBODY LABELING; CHROMOSOME LOCATION; ELECTRON MICROSCOPY; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROTUBULE; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PARKINSONISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN HYPERPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TAUOPATHY; ANIMAL; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING; TAUOPATHIES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; NEUROFIBRILLARY TANGLES; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TAU PROTEINS; TAUOPATHIES;

EID: 85006137585     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom6010006     Document Type: Review

References (190)

1. Bielschowsky, M. Die Silberimprägnation der Achsenzylinder. Neurol. Zentralb. (Leipzig) 1902, 13, 579-584. (In German)
2. Alzheimer, A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Zeits Psychiatry Psych. Med. 1907, 64, 146-148. (In German)
3. Jucker, M.; Beyreuther, K.; Haass, C.; Nitsch, R.; Christen, Y. Alzheimer: 100 Years and Beyond; Springer: Berlin, Germany, 2006.
4. Kidd, M. Paired helical filaments in electron microscopy of Alzheimer’s disease. Nature 1963, 197, 192-193. [CrossRef] [PubMed]
5. Terry, R.D. The fine structure of neurofibrillary tangles in Alzheimer’s disease. J. Neuropathol. Exp. Neurol. 1963, 22, 629-642. [CrossRef] [PubMed]
6. Crowther, R.A.; Wischik, C.M. Image reconstruction of the Alzheimer paired helical filament. EMBO J. 1985, 4, 3661-3665. [PubMed]
7. Wischik, C.M.; Crowther, R.A.; Stewart, M.; Roth, M. Subunit structure of paired helical filaments in Alzheimer’s disease. J. Cell Biol. 1985, 100, 1905-1912. [CrossRef] [PubMed]
8. Crowther, R.A. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc. Natl. Acad. Sci. USA 1991, 88, 2288-2292. [CrossRef] [PubMed]
9. Weingarten, M.D.; Lockwood, A.H.; Hwo, S.Y.; Kirschner, M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA 1975, 72, 1858-1862. [CrossRef] [PubMed]
10. Cleveland, D.W.; Hwo, S.Y.; Kirschner, M.W. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 1977, 116, 207-225. [CrossRef]
11. Cleveland, D.W.; Hwo, S.-Y.; Kirschner, M.W. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J. Mol. Biol. 1977, 116, 227-247. [CrossRef]
12. Pierre, M.; Nunez, J. Multisite phosphorylation of tau proteins from rat brain. Biochem. Biophys. Res. Commun. 1983, 115, 212-219. [CrossRef]
13. Jameson, L.; Frey, T.; Zeeberg, B.; Dalldorf, F.; Caplow, M. Inhibition of microtubule assembly by phosphorylation of microtubule-associated proteins. Biochemistry 1980, 19, 2472-2479. [CrossRef] [PubMed]
14. Lindwall, G.; Cole, R.D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 1984, 259, 5301-5305. [PubMed]
15. Binder, L.I.; Frankfurter, A.; Rebhun, L.I. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 1985, 101, 1371-1378. [CrossRef] [PubMed]
16. Papasozomenos, S.C.; Binder, L.I. Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil. Cytoskeleton 1987, 8, 210-226. [CrossRef] [PubMed]
17. Migheli, A.; Butler, M.; Brown, K.; Shelanski, M.L. Light and electron microscope localization of the microtubule-associated tau protein in rat brain. J. Neurosci. 1988, 8, 1846-1851. [PubMed]
18. Couchie, D.; Charrière-Bertrand, C.; Nunez, J. Expression of the mRNA for tau proteins during brain development and in cultured neurons and astroglial cells. J. Neurochem. 1988, 50, 1894-1899. [CrossRef] [PubMed]
19. Brion, J.; Passareiro, H.; Nunez, J.; Flament-Durand, J. Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d’Alzheimer. Arch. Biol. 1985, 95, 229-235. (In French).
20. Anderton, B.H.; Breinburg, D.; Downes, M.J.; Green, P.J.; Tomlinson, B.E.; Ulrich, J.; Wood, J.N.; Kahn, J. Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants. Nature 1982, 298, 84-86. [CrossRef] [PubMed]
21. Grundke-Iqbal, I.; Iqbal, K.; Quinlan, M.; Tung, Y.C.; Zaidi, M.S.; Wisniewski, H.M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 1986, 261, 6084-6089. [PubMed]
22. Grundke-Iqbal, I.; Iqbal, K.; Tung, Y.C.; Quinlan, M.; Wisniewski, H.M.; Binder, L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 1986, 83, 4913-4917. [CrossRef] [PubMed]
23. Ihara, Y.; Nukina, N.; Miura, R.; Ogawara, M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer’s disease. J. Biochem. 1986, 99, 1807-1810. [PubMed]
24. Masters, C.L.; Simms, G, Weinman, N.A.; Multhaup, G.; McDonald, B.L.; Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 1985, 82, 4245-4249. [CrossRef] [PubMed]
25. Masters, C.L.; Multhaup, G.; Simms, G.; Pottgiesser, J.; Martins, R.N.; Beyreuther, K. Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985, 4, 2757-2763. [PubMed]
26. Mori, H.; Kondo, J.; Ihara, Y. Ubiquitin is a component of paired helical filaments in Alzheimer’s disease. Science 1987, 235, 1641-1644. [CrossRef] [PubMed]
27. Perry, G.; Friedman, R.; Shaw, G.; Chau, V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. USA 1987, 84, 3033-3036. [CrossRef] [PubMed]
28. Yen, S.H.; Gaskin, F.; Fu, S.M. Neurofibrillary tangles in senile dementia of the Alzheimer type share an antigenic determinant with intermediate filaments of the vimentin class. Am. J. Pathol. 1983, 113, 373-381. [PubMed]
29. Yen, S.; Dickson, D.; Crowe, A. Alzheimer’s neurofibrillary tangles contain unique epitopes and epitopes in common with the heat-stable microtubule associated proteins tau and MAP2. Am. J. Pathol. 1987, 126, 81-91. [PubMed]
30. Wischik, C.M.; Novak, M.; Thøgersen, H.C.; Edwards, P.C.; Runswick, M.J.; Jakes, R, Walker, J.E.; Milstein, C.; Roth, M.; Klug, A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. USA 1988, 85, 4506-4510. [CrossRef] [PubMed]
31. Wischik, C.M.; Novak, M.; Edwards, P.C.; Klug, A.; Tichelaar, W.; Crowther, R.A. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. USA 1988, 85, 4884-4888. [CrossRef] [PubMed]
32. Novak, M.; Wischik, C.M.; Edwards, P.; Pannell, R.; Milstein, C. Characterisation of the first monoclonal antibody against the pronase resistant core of the Alzheimer PHF. Prog. Clin. Biol. Res. 1989, 317, 755-761. [PubMed]
33. Novak, M.; Jakes, R.; Edwards, P.C.; Milstein, C.; Wischik, C.M. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc. Natl. Acad. Sci. USA 1991, 88, 5837-5841. [CrossRef] [PubMed]
34. Resch, J.F.; Lehr, G.S.; Wischik, C.M. Design and synthesis of a potential affinity/cleaving reagent for beta-pleated sheet protein structures. Bioorg. Med. Chem. Lett. 1991, 1, 519-522. [CrossRef]
35. Lee, G.; Cowan, N.; Kirschner, M. The primary structure and heterogeneity of tau protein from mouse brain. Science 1988, 239, 285-288. [CrossRef] [PubMed]
36. Goedert, M.; Wischik, C.M.; Crowther, R.A.; Walker, J.E.; Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA 1988, 85, 4051-4055. [CrossRef] [PubMed]
37. Delacourte, A.; Defossez, A. Alzheimer’s disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J. Neurol. Sci. 1986, 76, 173-186. [CrossRef]
38. Kosik, K.S.; Joachim, C.L.; Selkoe, D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1986, 83, 4044-4048. [CrossRef] [PubMed]
39. Nukina, N.; Ihara, Y. One of the antigenic determinants of paired helical filaments is related to tau protein. J. Biochem. 1986, 99, 1541-1544. [PubMed]
40. Wood, J.G.; Mirra, S.S.; Pollock, N.J.; Binder, L.I. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc. Natl. Acad. Sci. USA 1986, 83, 4040-4043. [CrossRef] [PubMed]
41. Montejo de Garcini, E.; Serrano, L.; Avila, J. Self assembly of microtubule associated protein tau into filaments resembling those found in Alzheimer disease. Biochem. Biophys. Res. Commun. 1986, 141, 790-796. [CrossRef]
42. Neve, R.L.; Harris, P.; Kosik, K.S.; Kurnit, D.M.; Donlon, T.A. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Mol. Brain Res. 1986, 1, 271-280. [CrossRef]
43. Donlon, T.; Harris, P.; Neve, R. Localization of microtubule-associated protein tau (MTBT1) to chromosome 17q21 (Abstract). Cytogenet. Cell Genet. 1987, 46, 607.
44. Goedert, M.; Spillantini, M.; Potier, M.; Ulrich, J.; Crowther, R. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain. EMBO J. 1989, 8, 393-399. [PubMed]
45. Goedert, M.; Spillantini, M.G.; Jakes, R.; Rutherford, D.; Crowther, R. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 1989, 3, 519-526. [CrossRef]
46. Goedert, M.; Jakes, R. Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990, 9, 4225-4230. [PubMed]
47. Goedert, M.; Spillantini, M.G.; Crowther, R.A. Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system. Proc. Natl. Acad. Sci. USA 1992, 89, 1983-1987. [CrossRef] [PubMed]
48. Jovanov-Milošević, N.; Petrović, D.; Sedmak, G.; Vukšić, M.; Hof, P.R.; Šimić, G. Human fetal tau protein isoform: Possibilities for Alzheimer’s disease treatment. Int. J. Biochem. Cell Biol. 2012, 44, 1290-1294. [CrossRef] [PubMed]
49. Greenberg, S.G.; Davies, P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. USA 1990, 87, 5827-5831. [CrossRef] [PubMed]
50. Mulot, S.F.; Hughes, K.; Woodgett, J.R.; Anderton, B.H.; Hanger, D.P. PHF-tau from Alzheimer’s brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta. FEBS Lett. 1994, 349, 359-364. [CrossRef]
51. Wolozin, B.L.; Pruchnicki, A.; Dickson, D.W.; Davies, P. A neuronal antigen in the brains of Alzheimer patients. Science 1986, 232, 648-650. [CrossRef] [PubMed]
52. Flament, S.; Delacourte, A. Abnormal tau species are produced during Alzheimer’s disease neurodegenerating process. FEBS Lett. 1989, 247, 213-216. [CrossRef]
53. Lee, V.M.; Balin, B.J.; Otvos, L.; Trojanowski, J.Q. A68: A major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991, 251, 675-678. [CrossRef] [PubMed]
54. Lai, R.Y.; Gertz, H.N, Wischik, D.J.; Xuereb, J.H.; Mukaetova-Ladinska, E.B.; Harrington, C.R.; Edwards, P.C.; Mena, R.; Paykel, E.S.; Brayne, C.; et al. Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer’s disease. Neurobiol. Aging 1995, 16, 433-445. [CrossRef]
55. Wischik, C.M.; Edwards, P.C.; Lai, R.Y.; Gertz, H.N.; Xuereb, J.H.; Paykel, E.S.; Brayne, C.; Huppert, F.A.; Mukaetova-Ladinska, E.B.; Mena, R. Quantitative analysis of tau protein in paired helical filament preparations: Implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer’s disease. Neurobiol. Aging 1995, 16, 409-417, discussion 418-431. [CrossRef]
56. Jakes, R.; Novak, M.; Davison, M, Wischik, C.M. Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer’s disease. EMBO J. 1991, 10, 2725-2729. [PubMed]
57. Wischik, C.; Lai, R.; Harrington, C. Modelling prion-like processing of tau protein in Alzheimer’s disease for pharmaceutical development. In Brain Microtubule Associated Proteins: Modifications in Disease; Avila, J., Brandt, R., Kosik, K., Eds.; Harwood Academic Publishers: Amsterdam, The Nederland, 1997; pp. 185-241.
58. Gu, Y.; Oyama, F.; Ihara, Y. Tau is widely expressed in rat tissues. J. Neurochem. 1996, 67, 1235-1244. [CrossRef] [PubMed]
59. Qiang, L.; Yu, W.; Andreadis, A.; Luo, M.; Baas, P.W. Tau protects microtubules in the axon from severing by katanin. J. Neurosci. 2006, 26, 3120-3129. [CrossRef] [PubMed]
60. Takei, Y.; Teng, J.; Harada, A.; Hirokawa, N. Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J. Cell Biol. 2000, 150, 989-1000. [CrossRef] [PubMed]
61. Buée, L.; Bussière, T.; Buée-Scherrer, V.; Delacourte, A.; Hof, P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 2000, 33, 95-130. [CrossRef]
62. Morishima-Kawashima, M.; Hasegawa, M.; Takio, K.; Suzuki, M.; Yoshida, H.; Watanabe, A.; Titani, K.; Ihara, Y. Hyperphosphorylation of tau in PHF. Neurobiol. Aging 1995, 16, 365-371, discussion 371-380. [CrossRef]
63. Bretteville, A.; Ando, K.; Ghestem, A.; Loyens, A.; Bégard, S.; Beauvillain, J.-C.; Sergeant, N.; Hamdane, M.; Buée, L. Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes. PLoS ONE 2009, 4, e4843. [CrossRef] [PubMed]
64. Šimić, G.; Diana, A.; Hof, P.R. Phosphorylation pattern of tau associated with distinct changes of the growth cone cytoskeleton. Prog. Mol. Subcell. Biol. 2003, 32, 33-48. [PubMed]
65. Kingwell, K. Neurodegenerative disease: Targeting tau acetylation attenuates neurodegeneration. Nat. Rev. Drug Discov. 2015, 14, 748-749. [CrossRef] [PubMed]
66. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239-259. [CrossRef] [PubMed]
67. Braak, H.; Alafuzoff, I.; Arzberger, T.; Kretzschmar, H.; Tredici, K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, 112, 389-404. [CrossRef] [PubMed]
68. Ding, H.; Dolan, P.J.; Johnson, G.V.W. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J. Neurochem. 2008, 106, 2119-2130. [CrossRef] [PubMed]
69. Huang, D.Y, Weisgraber, K.H.; Goedert, M.; Saunders, A.M.; Roses, A.D.; Strittmatter, W.J. ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Neurosci. Lett. 1995, 192, 209-212. [CrossRef]
70. Reynolds, C.H.; Garwood, C.J.; Wray, S.; Price, C.; Kellie, S.; Perera, T.; Zvelebil, M.; Yang, A.; Sheppard, P.W.; Varndell, I.M.; et al. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase C1, Grb2, and Src family kinases. J. Biol. Chem. 2008, 283, 18177-18186. [CrossRef] [PubMed]
71. Surridge, C.D.; Burns, R.G. The difference in the binding of phosphatidylinositol distinguishes MAP2 from MAP2C and Tau. Biochemistry 1994, 33, 8051-8057. [CrossRef] [PubMed]
72. Flanagan, L.A.; Cunningham, C.C.; Chen, J.; Prestwich, G.D.; Kosik, K.S.; Janmey, P.A. The structure of divalent cation-induced aggregates of PIP2 and their alteration by gelsolin and tau. Biophys. J. 1997, 73, 1440-1447. [CrossRef]
73. Morris, M.; Maeda, S.; Vossel, K.; Mucke, L. The many faces of tau. Neuron 2011, 70, 410-426. [CrossRef] [PubMed]
74. Himmelstein, D.S.; Ward, S.M.; Lancia, J.K.; Patterson, K.R.; Binder, L.I. Tau as a therapeutic target in neurodegenerative disease. Pharmacol. Ther. 2012, 136, 8-22. [CrossRef] [PubMed]
75. Klein, C.; Kramer, E.-M.; Cardine, A.-M.; Schraven, B.; Brandt, R.; Trotter, J. Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau. J. Neurosci. 2002, 22, 698-707. [PubMed]
76. Jadhav, S.; Cubinkova, V.; Zimova, I.; Brezovakova, V.; Madari, A.; Cigankova, V.; Zilka, N. Tau-mediated synaptic damage in Alzheimer’s disease. Transl. Neurosci. 2015, 6, 214-226. [CrossRef]
77. Mondragón-Rodríguez, S.; Trillaud-Doppia, E.; Dudilot, A.; Bourgeois, C.; Lauzon, M.; Leclerc, N.; Boehm, J. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J. Biol. Chem. 2012, 287, 32040-32053. [CrossRef] [PubMed]
78. Ahmed, T.; van der Jeugd, A.; Blum, D.; Galas, M.-C.; D’Hooge, R.; Buée, L.; Balschun, D. Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. Neurobiol. Aging 2014, 35, 2474-2478. [CrossRef] [PubMed]
79. Regan, P.; Piers, T.; Yi, J.-H.; Kim, D.-H.; Huh, S.; Park, S.J.; Ryu, J.H.; Whitcomb, D.J.; Cho, K. Tau phosphorylation at serine 396 residue is required for hippocampal LTD. J. Neurosci. 2015, 35, 4804-4812. [CrossRef] [PubMed]
80. Sultan, A.; Nesslany, F.; Violet, M.; Bégard, S.; Loyens, A.; Talahari, S.; Mansuroglu, Z.; Marzin, D.; Sergeant, N.; Humez, S, et al. Nuclear tau, a key player in neuronal DNA protection. J. Biol. Chem. 2011, 286, 4566-4575. [CrossRef] [PubMed]
81. Perez, M.; Santa-Maria, I.; de Gomez Barreda, E.; Zhu, X.; Cuadros, R.; Cabrero, J.R.; Sanchez-Madrid, F.; Dawson, H.N.; Vitek, M.P.; Perry, G, et al. Tau-an inhibitor of deacetylase HDAC6 function. J. Neurochem. 2009, 109, 1756-1766. [CrossRef] [PubMed]
82. Leyk, J.; Goldbaum, O.; Noack, M.; Richter-Landsberg, C. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance. J. Mol. Neurosci. 2015, 55, 1031-1046. [CrossRef] [PubMed]
83. Davies, P.; Maloney, A.J. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976. [CrossRef]
84. Whitehouse, P.J.; Price, D.L.; Clark, A.W.; Coyle, J.T.; DeLong, M.R. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10, 122-126. [CrossRef] [PubMed]
85. Glenner, G.G, Wong, C.W. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120, 885-890. [CrossRef]
86. Wong, C.W.; Quaranta, V.; Glenner, G.G. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc. Natl. Acad. Sci. USA 1985, 82, 8729-8732. [CrossRef] [PubMed]
87. Glenner, G.G.; Wong, C.W. Alzheimer’s disease and Down’s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984, 122, 1131-1135. [CrossRef]
88. Goate, A.; Chartier-Harlin, M.C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991, 349, 704-706. [CrossRef] [PubMed]
89. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci. 1991, 12, 383-388. [CrossRef]
90. Hardy, J.A.; Higgins, G.A. Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992, 256, 184-185. [CrossRef] [PubMed]
91. Blanquet, V.; Goldgaber, D.; Turleau, C.; Créau-Goldberg, N.; Delabar, J.; Sinet, P.M.; Roudier, M.; de Grouchy, J. The beta amyloid protein (AD-AP) cDNA hybridizes in normal and Alzheimer individuals near the interface of 21q21 and q22.1. Ann. Génétique 1987, 30, 68-69.
92. Robakis, N, Wisniewski, H.; Jenkins, E.; Devine-Gage, E.; Houck, G.; Yao, X.; Ramakrishna, N, Wolfe, G.; Silverman, W.; Brown, W. Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet 1987, 1, 384-385. [CrossRef]
93. St George-Hyslop, P.H.; Tanzi, R.E.; Polinsky, R.J.; Haines, J.L.; Nee, L.; Watkins, P.C.; Myers, R.H.; Feldman, R.G.; Pollen, D.; Drachman, D, et al. The genetic defect causing familial Alzheimer’s disease maps on chromosome 21. Science 1987, 235, 885-890. [CrossRef] [PubMed]
94. Goldgaber, D.; Lerman, M.; McBride, W.; Saffiotti, U.; Gajdusek, D. Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer’s disease, Down’s syndrome and aging. J. Neural Transm. 1987, 24, 23-28.
95. Van Broeckhoven, C.; Haan, J.; Bakker, E.; Hardy, J.; van Hul, W.; Webnert, A; Vlis, M.; Roos, R. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science 1990, 248, 1120-1122. [CrossRef] [PubMed]
96. Levy, E.; Carman, M.; Fernandez-Madrid, I. Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990, 248, 1124-1126. [CrossRef] [PubMed]
97. Lowenberg, K.; Waggoner, R. Familial organic psychosis (Alzheimer’s type). Arch. Neurol. 1934, 31, 737-754. [CrossRef]
98. St George-Hyslop, P.; Haines, J.; Rogaev, E.; Mortilla, M.; Vaula, G.; Pericak-Vance, M.; Foncin, J.F.; Montesi, M.; Bruni, A.; Sorbi, S, et al. Genetic evidence for a novel familial Alzheimer’s disease locus on chromosome 14. Nat. Genet. 1992, 2, 330-334. [CrossRef] [PubMed]
99. Sherrington, R.; Rogaev, E.I.; Liang, Y.; Rogaeva, E.A.; Levesque, G.; Ikeda, M.; Chi, H.; Lin, C.; Li, G.; Holman, K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995, 375, 754-760. [CrossRef] [PubMed]
100. Schellenberg, G.D.; Bird, T.D.; Wijsman, E.M.; Orr, H.T.; Anderson, L.; Nemens, E.; White, J.A.; Bonnycastle, L.; Weber, J.L.; Alonso, M.E. Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science 1992, 258, 668-671. [CrossRef] [PubMed]
101. Levy-Lahad, E, Wasco, W.; Poorkaj, P.; Romano, D.M.; Oshima, J.; Pettingell, W.H.; Yu, C.E.; Jondro, P.D.; Schmidt, S.D.; Wang, K, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995, 269, 973-977. [CrossRef] [PubMed]
102. Czech, C.; Tremp, G.; Pradier, L. Presenilins and Alzheimer’s disease: Biological functions and pathogenic mechanisms. Prog. Neurobiol. 2000, 60, 363-384. [CrossRef]
103. Citron, M, Westaway, D.; Xia, W.; Carlson, G.; Diehl, T.; Levesque, G.; Johnson-Wood, K.; Lee, M.; Seubert, P.; Davis, A, et al. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 1997, 3, 67-72. [CrossRef] [PubMed]
104. Okochi, M.; Steiner, H.; Fukumori, A.; Tanii, H.; Tomita, T.; Tanaka, T.; Iwatsubo, T.; Kudo, T.; Takeda, M.; Haass, C. Presenilins mediate a dual intramembranous -secretase cleavage of Notch-1. EMBO J. 2002, 21, 5408-5416. [CrossRef] [PubMed]
105. De Strooper, B.; Iwatsubo, T.; Wolfe, M.S. Presenilins and -secretase: Structure, function, and role in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2012. [CrossRef] [PubMed]
106. Shen, J.; Bronson, R.T.; Chen, D.F.; Xia, W.; Selkoe, D.J.; Tonegawa, S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 1997, 89, 629-639. [CrossRef]
107. Van Groen, T. DNA Methylation and Alzheimer’s Disease. In Epigenetics of Aging; Tollefsbol, T., Ed.; Springer: New York, NY, USA, 2010; pp. 315-326.
108. Strittmatter, W.J.; Saunders, A.M.; Schmechel, D.; Pericak-Vance, M.; Enghild, J.; Salvesen, G.S.; Roses, A.D. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90, 1977-1981. [CrossRef] [PubMed]
109. Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.; George-Hyslop, P.H.; Pericak-Vance, M.A.; Joo, S.H.; Rosi, B.L.; Gusella, J.F.; Crapper-MacLachlan, D.R.; Alberts, M.J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993, 43, 1467-1472. [CrossRef] [PubMed]
110. Strittmatter, W.J. Old drug, new hope for Alzheimer’s disease. Science 2012, 335, 1447-1448. [CrossRef] [PubMed]
111. Mawuenyega, K.G.; Sigurdson, W.; Ovod, V.; Munsell, L.; Kasten, T.; Morris, J.C.; Yarasheski, K.E.; Bateman, R.J. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 2010. [CrossRef] [PubMed]
112. Castellano, J.M.; Kim, J.; Stewart, F.R.; Jiang, H.; DeMattos, R.B.; Patterson, B.W.; Fagan, A.M.; Morris, J.C.; Mawuenyega, K.G.; Cruchaga, C, et al. Human apoE isoforms differentially regulate brain amyloid- peptide clearance. Sci. Transl. Med. 2011. [CrossRef] [PubMed]
113. Qu, B.-X.; Gong, Y.; Moore, C.; Fu, M.; German, D.C.; Chang, L.-Y.; Rosenberg, R.; Diaz-Arrastia, R. Beta-amyloid auto-antibodies are reduced in Alzheimer’s disease. J. Neuroimmunol. 2014, 274, 168-173. [CrossRef] [PubMed]
114. Cacabelos, R. Pharmacogenetic basis for therapeutic optimization in Alzheimer’s disease. Mol. Diagn. Ther. 2007, 11, 385-405. [CrossRef] [PubMed]
115. Hollingworth, P.; Harold, D.; Sims, R.; Gerrish, A.; Lambert, J.; Carrasquillo, M.; Abraham, R.; Hamshere, M.; Pahwa, J.; Moskvina, V, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat. Genet. 2011, 43, 429-435. [CrossRef] [PubMed]
116. Naj, A.; Jun, G.; Beecham, G.; Wang, L.; Vardarajan, B.; Buros, J.; Gallins, P.; Buxbaum, J.; Jarvik, G.; Crane, P, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat. Genet. 2011, 43, 436-441. [CrossRef] [PubMed]
117. Lardenoije, R.; Iatrou, A.; Kenis, G.; Kompotis, K.; Steinbusch, H.W.M.; Mastroeni, D.; Coleman, P.; Lemere, C.A.; Hof, P.R.; van den Hove, D.L.A, et al. The epigenetics of aging and neurodegeneration. Prog. Neurobiol. 2015, 131, 21-64. [CrossRef] [PubMed]
118. Jonsson, T.; Stefansson, H.; Steinberg, S.; Jonsdottir, I.; Jonsson, P.V.; Snaedal, J.; Bjornsson, S.; Huttenlocher, J.; Levey, A.I.; Lah, J.J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med. 2013, 368, 107-116. [CrossRef] [PubMed]
119. Cruchaga, C.; Karch, C.M.; Jin, S.C.; Benitez, B.A.; Cai, Y.; Guerreiro, R.; Harari, O.; Norton, J.; Budde, J.; Bertelsen, S, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease. Nature 2014, 505, 550-554. [CrossRef] [PubMed]
120. Guerreiro, R.; Wojtas, A.; Bras, J.; Carrasquillo, M.; Rogaeva, E.; Majounie, E.; Cruchaga, C.; Sassi, C.; Kauwe, J.S. K.; Younkin, S, et al. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med. 2013, 368, 117-127. [CrossRef] [PubMed]
121. Arriagada, P.V.; Growdon, J.H.; Hedley-Whyte, E.T.; Hyman, B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992, 42, 631-639. [CrossRef] [PubMed]
122. Bierer, L.M.; Hof, P.R.; Purohit, D.P.; Carlin, L.; Schmeidler, J.; Davis, K.L.; Perl, D.P. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Arch. Neurol. 1995, 52, 81-88. [CrossRef] [PubMed]
123. Bancher, C.; Brunner, C.; Lassmann, H.; Budka, H.; Jellinger, K.; Wiche, G.; Seitelberger, F.; Grundke-Iqbal, I.; Iqbal, K.; Wisniewski, H.M. Accumulation of abnormally phosphorylated _ precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain Res. 1989, 477, 90-99. [CrossRef]
124. Braak, H.; Braak, E.; Strothjohann, M. Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci. Lett. 1994, 171, 1-4. [CrossRef]
125. Joshi, Y.B.; Praticò, D. Neuroinflammation and Alzheimer’s disease: Lessons learned from 5-lypoxigenase. Transl. Neurosci. 2014, 5, 197-202. [CrossRef]
126. Wang, H.-Y.; Stucky, A.; Hahn, C.-G.; Wilson, R.; Bennett, D.; Arnold, S. BDNF-trkB signaling in late life cognitive decline and Alzheimer’s disease. Transl. Neurosci. 2011, 2, 91-100. [CrossRef]
127. Pollock, N.; Mirra, S.; Binder, L.; Hansen, L.; Wood, J. Filamentous aggregates in Pick’s disease, progressive supranuclear palsy, and Alzheimer’s disease share antigenic determinants with microtubule-associated protein, tau. Lancet 1986, 204-205. [CrossRef]
128. Sergeant, N.; Delacourte, A.; Buée, L. Tau protein as a differential biomarker of tauopathies. Biochim. Biophys. Acta 2005, 1739, 179-197. [CrossRef] [PubMed]
129. Flament, S.; Delacourte, A.; Verny, M.; Hauw, J.J.; Javoy-Agid, F. Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol. 1991, 81, 591-596. [CrossRef] [PubMed]
130. Ksiezak-Reding, H.; Morgan, K.; Mattiace, L.A.; Davies, P.; Liu, W.K.; Yen, S.H.; Weidenheim, K.; Dickson, D.W. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am. J. Pathol. 1994, 145, 1496-1508. [PubMed]
131. Šimić, G. Pathological tau proteins in argyrophilic grain disease. Lancet Neurol. 2002. [CrossRef]
132. Delacourte, A.; Robitaille, Y.; Sergeant, N.; Buée, L.; Hof, P.R.; Wattez, A.; Laroche-Cholette, A.; Mathieu, J.; Chagnon, P.; Gauvreau, D. Specific pathological tau protein variants characterize Pick’s disease. J. Neuropathol. Exp. Neurol. 1996, 55, 159-168. [CrossRef] [PubMed]
133. Spillantini, M.G.; Goedert, M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998, 21, 428-433. [CrossRef]
134. Wilhelmsen, K.C.; Lynch, T.; Pavlou, E.; Higgins, M.; Nygaard, T.G. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am. J. Hum. Genet. 1994, 55, 1159-1165. [PubMed]
135. Spillantini, M.G.; Goedert, M.; Crowther, R.A.; Murrell, J.R.; Farlow, M.R.; Ghetti, B. Familial multiple system tauopathy with presenile dementia: A disease with abundant neuronal and glial tau filaments. Proc. Natl. Acad. Sci. USA 1997, 94, 4113-4118. [CrossRef] [PubMed]
136. Murrell, J.R.; Koller, D.; Foroud, T.; Goedert, M.; Spillantini, M.G.; Edenberg, H.J.; Farlow, M.R.; Ghetti, B. Familial multiple-system tauopathy with presenile dementia is localized to chromosome 17. Am. J. Hum. Genet. 1997, 61, 1131-1138. [CrossRef] [PubMed]
137. Foster, N.L, Wilhelmsen, K.; Sima, A.A.; Jones, M.Z.; D’Amato, C.J.; Gilman, S. Frontotemporal dementia and parkinsonism linked to chromosome 17: A consensus conference. Conference Participants. Ann. Neurol. 1997, 41, 706-715. [CrossRef] [PubMed]
138. Spillantini, M.G.; Murrell, J.R.; Goedert, M.; Farlow, M.R.; Klug, A.; Ghetti, B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA 1998, 95, 7737-7741. [CrossRef] [PubMed]
139. Poorkaj, P.; Bird, T.D, Wijsman, E.; Nemens, E.; Garruto, R.M.; Anderson, L.; Andreadis, A, Wiederholt, W.C.; Raskind, M.; Schellenberg, G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998, 43, 815-825. [CrossRef] [PubMed]
140. Hutton, M.; Lendon, C.; Rizzu, P.; Baker, M.; Froelich, S.; Houlden, H.; Pickering-Brown, S.; Chakraverty, S.; Isaacs, A.; Grover, A.; Hackett, J, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393, 702-705. [CrossRef] [PubMed]
141. Hasegawa, M.; Smith, M.J.; Goedert, M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 1998, 437, 207-210. [CrossRef]
142. Hong, M.; Zhukareva, V.; Vogelsberg-Ragaglia, V.; Wszolek, Z.; Reed, L.; Miller, B.I.; Geschwind, D.H.; Bird, T.D.; McKeel, D.; Goate, A.; et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998, 282, 1914-1917.
143. [CrossRef] [PubMed]
144. Šimić, G.; Gnjidić, M.; Kostović, I. Cytoskeletal changes as an alternative view on pathogenesis of Alzheimer’s disease. Period. Biol. 1998, 100, 165-173.
145. Bhatia, N.; Hall, G.F. Untangling the role of tau in Alzheimer’s disease: A unifying hypothesis. Transl. Neurosci. 2013, 4, 115-133. [CrossRef]
146. Dermaut, B.; Kumar-Singh, S.; Engelborghs, S.; Theuns, J.; Rademakers, R.; Saerens, J.; Pickut, B.A.; Peeters, K.; van den Broeck, M.; Vennekens, K, et al. A novel presenilin 1 mutation associated with Pick’s disease but not beta-amyloid plaques. Ann. Neurol. 2004, 55, 617-626. [CrossRef] [PubMed]
147. Vandrovcova, J.; Pittman, A.M.; Malzer, E.; Abou-Sleiman, P.M.; Lees, A.J.; Wood, N.W.; de Silva, R. Association of MAPT haplotype-tagging SNPs with sporadic Parkinson’s disease. Neurobiol. Aging 2009, 30, 1477-1482. [CrossRef] [PubMed]
148. Dawson, H.N.; Ferreira, A.; Eyster, M.V.; Ghoshal, N.; Binder, L.I.; Vitek, M.P. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 2001, 114, 1179-1187. [PubMed]
149. Terry, R.D. The pathogenesis of Alzheimer’s disease: An alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. 1996, 55, 1023-1025. [CrossRef] [PubMed]
150. Kopeikina, K.; Hyman, B.; Spires-Jones, T. Soluble forms of tau are toxic in Alzheimer’s disease. Transl. Neurosci. 2012, 3, 223-233. [CrossRef] [PubMed]
151. Harrington, C.R.; Mukaetova-Ladinska, E.B.; Hills, R.; Edwards, P.C.; de Montejo Garcini, E.; Novak, M.; Wischik, C.M. Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1991, 88, 5842-5846. [CrossRef] [PubMed]
152. Novak, M.; Kabat, J.; Wischik, C.M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer’s disease paired helical filament. EMBO J. 1993, 12, 365-370. [PubMed]
153. Wischik, C.M.; Edwards, P.C.; Lai, R.Y.; Roth, M.; Harrington, C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. USA 1996, 93, 11213-11218. [CrossRef] [PubMed]
154. Harrington, C.R.; Storey, J.M.D.; Clunas, S.; Harrington, K.A.; Horsley, D.; Ishaq, A.; Kemp, S.J.; Larch, C.P.; Marshall, C.; Nicoll, S.L, et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer’s Disease. J. Biol. Chem. 2015, 290, 10862-10875. [CrossRef] [PubMed]
155. Hrnkova, M.; Zilka, N.; Minichova, Z.; Koson, P.; Novak, M. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res. 2007, 1130, 206-213. [CrossRef] [PubMed]
156. Zilka, N.; Filipcik, P.; Koson, P.; Fialova, L.; Skrabana, R.; Zilkova, M.; Rolkova, G.; Kontsekova, E.; Novak, M. Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 2006, 580, 3582-3588. [CrossRef] [PubMed]
157. Wang, Y.; Martinez-Vicente, M.; Krüger, U.; Kaushik, S.; Wong, E.; Mandelkow, E.M.; Cuervo, A.M.; Mandelkow, E. Tau fragmentation, aggregation and clearance: The dual role of lysosomal processing. Hum. Mol. Genet. 2009, 18, 4153-4170. [CrossRef] [PubMed]
158. Wischik, C.M.; Harrington, C.R.; Storey, J.M.D. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem. Pharmacol. 2014, 88, 529-539. [CrossRef] [PubMed]
159. Mukaetova-Ladinska, E.B.; Garcia-Siera, F.; Hurt, J.; Gertz, H.J.; Xuereb, J.H.; Hills, R.; Brayne, C.; Huppert, F.A.; Paykel, E.S.; McGee, M, et al. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer’s disease. Am. J. Pathol. 2000, 157, 623-636. [CrossRef]
160. Callahan, L.M.; Vaules, W.A.; Coleman, P.D. Progressive reduction of synaptophysin message in single neurons in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2002, 61, 384-395. [PubMed]
161. Liu, X.; Brun, A. Regional and laminar synaptic pathology in frontal lobe degeneration of non-Alzheimer type. Int. J. Geriatr. Psychiatry 1996, 11, 47-55. [CrossRef]
162. Suzuki, K.; Parker, C.C.; Pentchev, P.G.; Katz, D.; Ghetti, B.; D’Agostino, A.N.; Carstea, E.D. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol. 1995, 89, 227-238. [CrossRef] [PubMed]
163. Dujardin, S.; Lécolle, K.; Caillierez, R.; Bégard, S.; Zommer, N.; Lachaud, C.; Carrier, S.; Dufour, N.; Aurégan, G.; Winderickx, J.; et al. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: Relevance to sporadic tauopathies. Acta Neuropathol. Commun. 2014. [CrossRef] [PubMed]
164. Hall, G.F.; Patuto, B.A. Is tau ready for admission to the prion club? Prion 2012, 6, 223-233. [CrossRef] [PubMed]
165. Iba, M.; Guo, J.L.; McBride, J.D.; Zhang, B.; Trojanowski, J.Q.; Lee, V.M.-Y. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J. Neurosci. 2013, 33, 1024-1037. [CrossRef] [PubMed]
166. Frost, B.; Jacks, R.L.; Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284, 12845-12852. [CrossRef] [PubMed]
167. De Calignon, A.; Polydoro, M.; Suárez-Calvet, M, William, C.; Adamowicz, D.H.; Kopeikina, K.J.; Pitstick, R.; Sahara, N.; Ashe, K.H.; Carlson, G.A, et al. Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 2012, 73, 685-697. [CrossRef] [PubMed]
168. Liu, L.; Drouet, V.; Wu, J.W.; Witter, M.P.; Small, S.A.; Clelland, C.; Duff, K. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 2012, 7, e31302. [CrossRef] [PubMed]
169. Yanamandra, K.; Kfoury, N.; Jiang, H.; Mahan, T.E.; Ma, S.; Maloney, S.E.; Wozniak, D.F.; Diamond, M.I.; Holtzman, D.M. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013, 80, 402-414. [CrossRef] [PubMed]
170. Rubinsztein, D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443, 780-786. [CrossRef] [PubMed]
171. Holmes, B.B.; Furman, J.L.; Mahan, T.E.; Yamasaki, T.R.; Mirbaha, H.; Eades, W.C.; Belaygorod, L.; Cairns, N.J.; Holtzman, D.M.; Diamond, M.I. Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl. Acad. Sci. USA 2014, 111, E4376-E4385. [CrossRef] [PubMed]
172. Asai, H.; Ikezu, S.; Tsunoda, S.; Medalla, M.; Luebke, J.; Haydar, T.; Wolozin, B.; Butovsky, O.; Kügler, S.; Ikezu, T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 2015, 18, 1584-1593. [CrossRef] [PubMed]
173. Avila, J.; Gómez-Ramos, A.; Bolós, M. AD genetic risk factors and tau spreading. Front. Aging Neurosci. 2015, 7, 1088-1093. [CrossRef] [PubMed]
174. Le Corre, S.; Klafki, H.W.; Plesnila, N.; Hübinger, G.; Obermeier, A.; Sahagún, H.; Monse, B.; Seneci, P.; Lewis, J.; Eriksen, J, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. USA 2006, 103, 9673-9678. [CrossRef] [PubMed]
175. Varghese, M.; Ho, L.; Wang, J.; Zhao, W.; Levine, S.; Ono, K.; Mannino, S.; Pasinetti, G. Green coffee as a novel agent for Alzheimer’s disease prevention by attenuating diabetes. Transl. Neurosci. 2014, 5, 111-116. [CrossRef]
176. Berger, Z.; Ravikumar, B.; Menzies, F.M.; Oroz, L.G.; Underwood, B.R.; Pangalos, M.N.; Schmitt, I.; Wullner, U.; Evert, B.O.; O’Kane, C.J, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 2006, 15, 433-442. [CrossRef] [PubMed]
177. Troquier, L.; Caillierez, R.; Burnouf, S.; Fernandez-Gomez, F.J.; Grosjean, M.-E.; Zommer, N.; Sergeant, N.; Schraen-Maschke, S.; Blum, D.; Buée, L. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: A suitable therapeutic approach. Curr. Alzheimer Res. 2012, 9, 397-405. [CrossRef] [PubMed]
178. Dawidowitz, E.; Moe, J. Targeting tau for Alzheimer’s disease and related neurodegenerative disorders. Drug Discov. 2012, 3, 16-21.
179. Del Ser, T.; Steinwachs, K.C.; Gertz, H.J.; Andrés, M.V.; Gómez-Carrillo, B.; Medina, M.; Vericat, J.A.; Redondo, P.; Fleet, D.; León, T. Treatment of Alzheimer’s Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study. J. Alzheimers. Dis. 2013, 33, 205-215. [PubMed]
180. Baddeley, T.C.; McCaffrey, J.; Storey, J.M.D.; Cheung, J.K.S.; Melis, V.; Horsley, D.; Harrington, C.R.; Wischik, C.M. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer’s disease. J. Pharmacol. Exp. Ther. 2015, 352, 110-118. [CrossRef] [PubMed]
181. Wischik, C.M.; Staff, R.T.; Wischik, D.J.; Bentham, P.; Murray, A.D.; Storey, J.M.D.; Kook, K.A.; Harrington, C.R. Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer’s disease. J. Alzheimers. Dis. 2015, 44, 705-720. [PubMed]
182. Grinberg, L.T.; Wang, X.; Wang, C.; Sohn, P.D.; Theofilas, P.; Sidhu, M.; Arevalo, J.B.; Heinsen, H.; Huang, E.J.; Rosen, H.; et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol. 2013, 125, 581-593. [CrossRef] [PubMed]
183. Mohideen, S.; Yamasaki, Y.; Omata, Y.; Tsuda, L.; Yoshiike, Y. Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies. Sci. Rep. 2015. [CrossRef]
184. Melis, V.; Magbagbeolu, M.; Rickard, J.E.; Horsley, D.; Davidson, K.; Harrington, K.A.; Goatman, K.; Goatman, E.A.; Deiana, S.; Close, S.P, et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav. Pharmacol. 2015, 26, 353-368. [CrossRef] [PubMed]
185. Stack, C.; Jainuddin, S.; Elipenahli, C.; Gerges, M.; Starkova, N.; Starkov, A.; Jové, M.; Portero-Otin, M.; Launay, N.; Pujol, A, et al. Methylene blue upregulates Nrf2/ARE genes and prevents tau-relatd neurotoxicity. Hum. Mol. Genet. 2014, 23, 3716-3732. [CrossRef] [PubMed]
186. Pakavathkumar, P.; Sharma, G.; Kaushal, V.; Foveau, B.; LeBlanc, A. Methylene blue inhibits caspases by oxidation of the catalytic cysteine. Sci. Rep. 2015. [CrossRef] [PubMed]
187. Hochgräfe, K.; Sydow, A.; Matenia, D.; Cadinu, D.; Könen, S.; Petrova, O.; Pickhardt, M.; Goll, P.; Morellini, F.; Mandelkow, E, et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol. Commun. 2015. [CrossRef] [PubMed]
188. Bulic, B.; Pickhardt, M.; Mandelkow, E.-M.; Mandelkow, E. Tau protein and tau aggregation inhibitors. Neuropharmacology 2010, 59, 276-289. [CrossRef] [PubMed]
189. Jun, G.; Ibrahim-Verbaas, C.A.; Vronskaya, M.; Lambert, J.-C.; Chung, J.; Naj, A.C.; Kunkle, B.W.; Wang, L.-S.; Bis, J.C.; Bellenguez, C, et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol. Psychiatry 2015. [CrossRef] [PubMed]
190. Šimić, G.; Stanić, G.; Mladinov, M.; Jovanov-Milošević, N.; Kostović, I.; Hof, P.R. Does Alzheimer’s disease begin in the brainstem? Neuropathol. Appl. Neurobiol. 2009, 35, 532-554. [CrossRef] [PubMed]